Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
72 studies found for:    Melanoma (women OR woman OR female)
Show Display Options
RSS Create an RSS feed from your search for:
Melanoma (women OR woman OR female)
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma
Condition: Melanoma
Intervention: Behavioral: questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided
2 Completed Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass
Conditions: Breast Cancer;   Genitourinary Cancer;   Malignant Female Reproductive System Neoplasm;   Melanoma;   Sarcoma
Intervention: Procedure: Punch Biopsy
3 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Quality-of-Life Assessment
4 Recruiting Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Bevacizumab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
5 Recruiting Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
6 Recruiting Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Other: Laboratory Biomarker Analysis
7 Completed Vaccine Therapy in Treating Patients With Metastatic Cancer
Conditions: Lung Cancer;   Adult Soft Tissue Sarcoma;   Colorectal Cancer;   Bone Cancer;   Ovarian Sarcoma;   Melanoma;   Colon Cancer;   Rectal Cancer;   Breast Cancer;   Eye Cancer;   Uterine Sarcoma
Interventions: Drug: interleukin-2;   Drug: MAGE-12 peptide vaccine;   Drug: Montanide ISA-51
8 Completed
Has Results
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
9 Recruiting Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
Condition: Metastatic Melanoma
Intervention: Radiation: WBRT
10 Completed SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Intervention: Procedure: Surgery
11 Recruiting Neurotropic Melanoma of the Head and Neck
Condition: Neurotropic Melanoma of the Head and Neck
Interventions: Other: Observation;   Radiation: Radiation Therapy
12 Terminated Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Condition: Melanoma
Intervention:
13 Recruiting A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Condition: Melanoma
Interventions: Biological: Poly-ICLC;   Biological: Peptides
14 Completed Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Condition: Melanoma (Skin)
Interventions: Genetic: comparative genomic hybridization;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: immunohistochemistry staining method
15 Recruiting Dendritic Cell Activating Scaffold in Melanoma
Condition: Melanoma
Intervention: Biological: WDVAX
16 Completed Everolimus in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Intervention: Drug: everolimus
17 Suspended Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Conditions: Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Ocular Melanoma With Extraocular Extension;   Recurrent Uveal Melanoma;   Small Size Posterior Uveal Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Temozolomide;   Drug: Dacarbazine;   Other: Laboratory Biomarker Analysis
18 Active, not recruiting Dinaciclib in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Mucosal Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Intervention: Drug: dinaciclib
19 Recruiting Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Laboratory Biomarker Analysis
20 Suspended High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa;   Other: clinical observation

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years